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Background: Multiple myeloma is characterized by the presence of transformed neoplastic plasma cells in the
bone marrow and is generally considered to be an incurable disease. Successful treatments will likely require multi-faceted
approaches incorporating conventional drug therapies, immunotherapy and other novel treatments. Our lab previously
showed that a combination of transient lymphodepletion (sublethal whole body irradiation) and PD-1/PD-L1 blockade
generated anti-myeloma T cell reactivity capable of eliminating established disease. We hypothesized that blocking
a combination of checkpoint receptors in the context of low-dose, lymphodepleting whole body radiation would
boost anti-tumor immunity.
Methods: To test our central hypothesis, we utilized a 5T33 murine multiple myeloma model. Myeloma-bearing mice
were treated with a low dose of whole body irradiation and combinations of blocking antibodies to PD-L1, LAG-3,
TIM-3, CD48 (the ligand for 2B4) and CTLA4.
Results: Temporal phenotypic analysis of bone marrow from myeloma-bearing mice demonstrated that elevated
percentages of PD-1, 2B4, LAG-3 and TIM-3 proteins were expressed on T cells. When PD-L1 blockade was combined
with blocking antibodies to LAG-3, TIM-3 or CTLA4, synergistic or additive increases in survival were observed (survival
rates improved from ~30% to >80%). The increased survival rates correlated with increased frequencies of
tumor-reactive CD8 and CD4 T cells. When stimulated in vitro with myeloma cells, CD8 T cells from treated mice
produced elevated levels proinflammatory cytokines. Cytokines were spontaneously released from CD4 T cells
isolated from mice treated with PD-L1 plus CTLA4 blocking antibodies.
Conclusions: These data indicate that blocking PD-1/PD-L1 interactions in conjunction with other immune
checkpoint proteins provides synergistic anti-tumor efficacy following lymphodepletive doses of whole body irradiation.
This strategy is a promising combination strategy for myeloma and other hematologic malignancies.
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2B4, MyelomaBackground
Reports of immunotherapy-induced clinical responses have
brought the study of tumor immunity front and center in
the mission to eliminate cancer. Central to tumor immun-
ity is the killing potential of activated tumor-specific T cells.
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unless otherwise stated.animal models and cancer patients, but due to multiple im-
mune suppressive factors within the tumor microenviron-
ment, T cells fail to maintain an activated state against
progressing tumor and are rendered tolerant or exhausted.
T cell activation is initiated through tumor antigen recogni-
tion by the T cell receptor (TCR) and is regulated by a
balance of activation and inhibitory intracellular signals.
These signals are initiated by engagement of co-stimulatory
and co-inhibitory receptors with their cognate ligands. One
of the promising approaches to induce and maintainis is an Open Access article distributed under the terms of the Creative
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fere with signaling through inhibitory (also referred to
as immune checkpoint) receptors.
There are multiple known T cell checkpoint receptors,
and there is evidence that blocking interaction of these
receptors with their respective ligands can increase anti-
tumor immune responses. One of the most studied
checkpoint receptors is CTLA4. Cell surface CTLA4 ex-
pression is rapidly upregulated when T cells are activated,
and it is constitutively expressed on Foxp3+ regulatory T
cells [1]. Signaling through CTLA4 arrests T cell activation
by outcompeting co-stimulatory receptors (CD80 and
CD86) for binding to CD28. CTLA4 binding to CD28 re-
sults in reduced T cell survival, cytokine production and
T cell cycle arrest [2]. Testament to the importance of
CTLA4 in dampening T cell activation is the occurrence
of a lethal polyclonal lymphoproliferative disease that oc-
curs in CTLA4 knockout mice [3]. Antagonistic anti-
CTLA4 antibodies have been extensively tested in cancer
models as a strategy to activate anti-tumor immunity,
and CTLA4 was the first immune checkpoint targeted
in the clinic for cancer therapy. The anti-tumor effects
associated with blocking CTLA4 in vivo have been shown
to involve depletion of regulatory T cells as well as restor-
ing effector T cell function [4,5]. Notably, CTLA4 block-
ade results in increased ratios of effector CD8 T cells to
regulatory T cells in tumors, possibly due to higher levels
of CTLA4 expression by regulatory T cells [4]. In 2010,
a phase III randomized controlled clinical trial showed
prolonged survival of metastatic melanoma patients when
treated with the anti-CTLA4 antibody ipilimumab [6].
In melanoma patients, blocking CTLA4 produced a
host of immune-related toxic side effects (referred to as
immune-related adverse events). However, based on the
promising responses in melanoma patients, ipilimumab
was the first checkpoint-blocking antibody to be FDA ap-
proved (for the treatment of melanoma).
Our laboratory has focused on blocking the checkpoint
receptor programmed death receptor-1 (PD-1) pathway in
the treatment of myeloma. PD-1 (CD279) is an im-
munoglobulin superfamily transmembrane receptor that
is expressed on activated T cells, regulatory T cells, B cells
and NK cells. Ligands for PD-1 include PD-L1 (B7-H1,
CD274) and PD-L2 (B7-DC, CD273) [7]. PD-L2 expres-
sion is restricted to hematopoietic cells, notably myeloid
cells including dendritic cells and macrophages, but
PD-L1 is broadly expressed on hematopoietic and non-
hematopoietic cells as well as on a variety of murine
and human malignancies [8,9]. Most of data showing
the anti-tumor efficacy induced by blocking the PD-1/
PD-L1 inhibitory receptor axis has been generated from
preclinical and clinical studies involving solid tumors. Pre-
clinical studies have shown that blocking the PD-L1/PD-1
axis with anti-PD-L1 or anti-PD-1 antibodies promotesanti-tumor T cell responses in pancreatic carcinoma [10],
B16 melanoma [11], and CT26 colon carcinoma [12]. In a
recent clinical study, patients with colorectal cancer, renal
cell carcinoma or melanoma showed objective responses
to anti-PD-L1 therapy [13]. Patients with PD-L1+ tumors,
but not PD-L1− tumors, showed objective responses when
treated with an anti-PD-1 blocking antibody [14]. Clinic-
ally, combining anti-CTLA4 (ipilimumab) with anti-PD-1
(nivolumab) antibodies resulted in even greater anti-
tumor efficacy, as tumor regression occurred in 80% of
patients with advanced melanoma [15]. Importantly, im-
mune adverse events were qualitatively similar to that expe-
rienced with prior treatment of either antibody alone.
Less well-characterized T cell immune checkpoint re-
ceptors include lymphocyte activating gene 3 (LAG-3 or
CD223), T cell immunoglobulin and mucin domain 3
(TIM-3), 2B4 (CD244), and others. LAG-3 is a member
of the immunoglobulin (Ig) superfamily that binds to
MHC class II molecules, and has recently been reported
to also bind L-selectin [16]. LAG-3 is expressed on acti-
vated and tolerized T cells, NK cells, plasmacytoid den-
dritic cells, and regulatory T cells and it is known to
negatively regulate the expansion of activated T cells
[17,18]. Preclinical studies have shown that combined
treatment of LAG-3 and PD-1 blocking antibodies pro-
vided a synergistic anti-tumor effect [19]. The TIM fam-
ily of transmembrane receptor proteins includes several
members (TIM-1, 2, 3 and 4 in mice, but only TIM-1, 3
and 4 are known to be expressed in humans). Ligation
of TIM-1 regulates Th2 CD4 T cell responses, and in
mice, TIM-1 promotes CD4 T cell activation [20]. TIM-
3 is a checkpoint receptor that is co-expressed on PD-1+
CD8 T cells in mice harboring solid or hematologic malig-
nancies [21,22]. The ligand for TIM-3 is galectin-9 which
is expressed by multiple tumors. Reduced galactin-9 ex-
pression correlates with reduced disease progression in a
majority of solid tumors [23]. PD-1+TIM-3+ T cells de-
rived from patients with melanoma, non-small cell lung
cancer or non-Hodgkin’s lymphoma are defective in pro-
liferation and cytokine production [24-26]. TIM-3 is also
expressed on regulatory T cells, monocytes, NK cells, and
dendritic cells [27]. Data suggests that TIM-3 can play anti-
inflammatory or pro-inflammatory roles in cells depending
on the physiologic setting [28,29]. In a preclinical mouse
B16F10 melanoma model, combined blockade of TIM-3 and
PD-1, or TIM-3 and CTLA4, was more effective in prolong-
ing survival than blocking either protein alone [30]. In
addition, the combination of anti-CTLA4, anti-TIM-3 and
anti-LAG-3 produced further suppression of B16F10 tumor
growth [30]. These data demonstrate a mechanistic synergy
when multiple inhibitory receptors are blocked.
2B4 (CD244) engagement with CD48 was originally
described as facilitating CD8 T cell proliferation [31]. Re-
cent data examining hepatitis C-virus (HCV)-specific
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with low versus high 2B4 expression increased or de-
creased proliferation, respectively, and 2B4 blockade
preferentially increased proliferation of HCV CD8 T cells
with high 2B4 expression [32]. Similar to other checkpoint
proteins, 2B4 is upregulated on exhausted virus-specific
CD8 T cells [33]. Together these data suggest that 2B4
plays a role in the regulation of CD8 T cells.
Despite the promising results afforded by blocking
CTLA4 and the PD-1/PD-L1 axis in the treatment of
solid tumors, targeting these checkpoints in hematologic
malignancies has been relatively understudied. Multiple
myeloma is a hematologic malignancy involving plasma
cells. In humans, PD-L1 is expressed on CD138+ malig-
nant plasma cells [34-38]. We have shown that PD-1 is
upregulated on peripheral blood and bone marrow in
myeloma patients up to 30 days following autologous
transplant [35]. In humans, blocking the PD-L1/PD-1
axis may act to prevent inhibitory signaling when ef-
fector T cells engage with tumor cells and when T cells
are undergoing homeostatic expansion.
Our preclinical studies have demonstrated improved
anti-myeloma T cell immunity when the PD-1/PD-L1
axis is blocked. Using a murine model of myeloma, we
showed that administration of an anti-PD-L1 blocking
antibody elicits rejection of PD-L1 expressing tumor cells.
When anti-PD-L1 was administered immediately follow-
ing hematopoietic stem cell transplantation in combin-
ation with a tumor cell-based vaccine, myeloma was
eliminated in approximately 40% of treated mice [35].
We also reported that 5T33 tumor was eliminated in
approximately 50% of mice when treated with anti-PD-
L1 following radiation-induced lymphopenia [39]. Based
on these data and the data of others, we hypothesized that
blocking a combination of checkpoint receptors in the
context of lymphodepleting radiation would boost anti-
tumor immunity. The results presented here confirm the
hypothesis and show that PD-1/PD-L1 blockade in combin-
ation with either TIM-3, LAG-3 or CTLA4 blockade syner-
gistically improves the survival of myeloma bearing mice.
Results
Increased PD-1, TIM-3, LAG-3 and 2B4 expression on CD4
and CD8 T cells directly correlates with myeloma burden
Our previous work demonstrated that the PD-1/PD-L1
pathway is important in suppressing immune responses
to 5T33 myeloma, and that PD-1 expression on T cells
is related to 5T33 burden in the myeloma-resident tis-
sues (bone marrow, spleen and liver) [35,39]. Besides ex-
pression of the immune checkpoint protein PD-1, T cells
within tumor environments may develop a dysfunctional
phenotype accompanied by the increased expression of
other checkpoint proteins. We therefore examined CD4
and CD8 T cells for the expression of other checkpointreceptors over time in myeloma-bearing animals. GFP+
5T33 cells could be observed in the bone marrow as
early as 7 days after iv inoculation, with increasing accu-
mulation of myeloma cells over time (Figure 1A). When
myeloma-bearing mice became moribund (29-38 days
after 5T33 inoculation), 20-35% of the cells in the bone
marrow consisted of GFP+ tumor cells. As previously de-
scribed [39], there was a significant increase in the per-
centages of PD-1+ bone marrow-derived CD4 and CD8
T cells as early as 21 days after myeloma inoculation
(Figure 1B). As myeloma burden progressed, the percent-
ages of bone marrow-derived PD-1+ CD4 and CD8 T cells
increased to 40-70% and 30-50%, respectively. Similar to
the increase in PD-1 expression, increasing percentages of
T cells in the bone marrow expressed TIM-3, LAG-3 and
2B4 as myeloma burden progressed (Figure 1B). In con-
trast, percentages of T cells expressing TIM-1 or BTLA did
not increase over time. Similar results were also observed
in the spleen (Additional file 1: Figure S1). Together, these
data show that there is upregulated expression of multiple
checkpoint receptors on T cells in tissues where myeloma
cells are present, and that an accumulation of checkpoint-
expressing T cells occurs over time. In order to show that
checkpoint receptors are co-expressed on T cells, CD4
and CD8 cells in the bone marrow of moribund mice were
analyzed for PD-1, TIM-3, LAG-3 and 2B4 expression
using multicolor flow cytometry. For CD8 T cells
(Figure 1C, top row), PD-1 was co-expressed on 85% of
TIM-3+ cells, 67% of LAG-3+ cells, and 51% of 2B4+ cells.
For CD4 T cells (Figure 1C, bottom row), co-expression of
PD-1 was observed on 90% of TIM-3+ cells, 47% of
LAG-3+ cells, and 44% of 2B4+ cells. Notably, there were
also PD-1+ cells that did not co-express the other check-
points (upper left quadrants in Figure 1C), as well as
major subsets of LAG-3+ and 2B4+ cells that did not
co-express PD-1 (lower right quadrants in Figure 1C).
Next, we determined whether checkpoint ligands for
TIM-3, LAG-3 and CTLA4 were expressed on the tumor
and cells within the tumor microenvironment (i.e., spleen).
PD-L1 is highly expressed on 5T33 myeloma cells [35], but
the ligands for TIM-3 (galectin-9), LAG-3 (MHC class II),
and CTLA4 (CD80) are not (Additional file 2: Figure S2A).
In vitro irradiation with 500 cGy did not change the
galectin-9, MHC class II or CD80 expression on 5T33
myeloma cells. Not surprisingly, galectin-9, MHC class II
and CD80 is present on a variety of cells in the tumor
microenvironment including B cells, macrophages, DCs
and monocytes (Additional file 2: Figure S2B).
Immune checkpoint protein expression is increased on
CD8 T cells in mice treated with lymphodepleting
radiation and anti-PD-L1
We previously showed that blocking the PD-1/PD-L1 axis
with a PD-L1-specific monoclonal antibody synergized
Figure 1 (See legend on next page.)
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Figure 1 Expression of immune checkpoint proteins on T cells in bone marrow of myeloma bearing mice over time. KaLwRij mice were
inoculated with 2×106 5T33-GFP cells iv. Myeloma bearing mice were euthanized between days 7 and 28 and when moribund at days 29-40 after
myeloma injection. Femoral bone marrow cells were harvested and (A) GFP+ tumor cell accumulation was monitored by flow cytometry. CD4+
and CD8+ T cells in the bone marrow were analyzed by flow cytometry for expression of (B) PD-1, TIM-3, LAG-3, BTLA and 2B4 at each of the time
points indicated, or for surface expression of (C) CTLA4 when animals were moribund. T cells harvested from naïve non-myeloma bearing mice
were analyzed as controls. Immune checkpoint protein percentages were calculated based on isotype controls. (D) Expression of TIM-3 and PD-1,
LAG-3 and PD-1 or 2B4 and PD-1 on gated CD8+ or CD4+ T cells harvested from the BM of moribund mice. Data shown are representative of
more than four independent analyses. *p < 0.05, **p < 0.01, ***p < 0.001 as compared to T cells from naïve non-myeloma bearing mice.
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cilitate a T cell-mediated anti-myeloma response [39]. To
determine the influence of this treatment on T cell im-
mune checkpoint expression, mice with established mye-
loma were treated with 500 cGy WBI 7 days after 5T33
inoculation, followed by three treatments with anti–PD-
L1 or control IgG on days 5, 7 and 12 after WBI. On day
14 after WBI, CD8 T cells were harvested from bone mar-
row and analyzed for expression of PD-1, TIM-3, LAG-3
and 2B4 by flow cytometry. There were significant in-
creases in the percentages of CD8 T cells that expressed
TIM-3, LAG-3 or 2B4 in mice treated with anti-PD-L1 as
compared to controls treated with IgG1 (Figure 2A).
Interestingly, the mice treated with anti-PD-L1 also had a
marked increase in percentages of PD-1+ CD8 T cells
(Figure 2B), and relatively large percentages of the PD-1+
cells co-expressed TIM-3 (52%), LAG-3 (60%) or 2B4
(40%) (Figure 2B).
Blocking PD-L1 in combination with TIM-3, LAG-3 or
CTLA4 blockade synergize to improve the survival of
lymphodepleted myeloma-bearing mice
Since multiple immune checkpoint proteins are upregu-
lated on T cells in myeloma-bearing mice (Figure 1), and
blocking the PD-L1/PD-1 axis in lymphodepleted ani-
mals induces increased expression of LAG-3, TIM-3 and
2B4 checkpoint proteins (Figure 2), we hypothesized that
anti-myeloma immunity would be enhanced by blocking
combinations of immune checkpoints. Mice were inocu-
lated with 2×106 5T33 tumor cells iv, received 500 cGy
WBI 7 days after tumor cell inoculation, and were treated
with checkpoint blocking antibodies (200 ug of each
antibody ip) at the time points indicated in Figure 3A.
Administration of anti-PD-L1 alone eliminated mye-
loma in ~40% of mice (Figure 2B-E), which is consist-
ent with our previous results [39]. While treatment
with anti-TIM-3 or anti-LAG-3 alone had no affect on
survival (Figure 2B, C), co-administration of either
antibody with anti-PD-L1 synergistically improved sur-
vival rates to greater than 80% (Figure 2B, C). The
combination of anti-TIM-3 with anti-LAG-3 failed to
improve survival (Figure 2C). Therefore, PD-L1 block-
ade was necessary in order to see any survival benefit
from blocking the two other checkpoints. Survival wasalso significantly improved by combining anti-PD-L1
with anti-CTLA4 (Figure 2D). Anti-CTLA4 alone also
facilitated the elimination of myeloma in approximately
15% of animals. Since a blocking antibody to 2B4 was not
available, an antibody to the 2B4 ligand, CD48, was used
to block the 2B4/CD48 axis. As shown in Figure 3E, anti-
CD48 administered alone or with anti-PD-L1 failed to
have any impact on the elimination of myeloma.
In order to test if survivors from the experiments in
Figure 3B-D had developed anti-tumor memory, they
were challenged with 1×106 5T33 tumor cells iv 100-110
days after the initial tumor cell inoculation and followed
for tumor development. All survivors of the experiments
in Figure 3B-D survived the 5T33 re-challenge, indicat-
ing that blocking the indicated combinations of check-
point receptors does not compromise anti-tumor
immune memory (Figure 3F).
Combined checkpoint blockade increases the frequency
of myeloma-reactive CD8 and CD4 T cells
Since previous data from our laboratory demonstrated that
the increased survival of myeloma-bearing mice treated
with lymphodepleting WBI and anti-PD-L1 is T cell medi-
ated [39], we set out to determine if combined checkpoint
blockade increases numbers of functional tumor-reactive T
cells. To do this, mice were treated according to the sched-
ule in Figure 3A, but instead of 6 doses of blocking
antibody, they received 3 doses on days 12, 14 and 19 fol-
lowing tumor cell injection. Twenty-one days after tumor
cell injection, T cells were harvested from the spleens and
bone marrow and CD4 and CD8 T cells were enriched by
immunomagnetic cell sorting. Frequencies of tumor-
reactive IFN-γ-producing cells were then assessed in ELI-
SPOT assays. CD8 T cells were stimulated with wild-type
5T33 cells, while MHC class II-expressing 5T33 cells (engi-
neered to express CIITA) were used to stimulate CD4 T
cells. Both spleen and bone marrow-derived CD4 and CD8
T cells showed a significant increase in tumor-specific IFN-
γ producing cells when mice were treated with anti-PD-L1
in combination with anti-TIM-3, or anti-LAG-3 or anti-
CTLA4 as compared to anti-PD-L1 alone (Figure 4A).
To determine if there were differences in bulk cytokine
production, splenic CD8 T cells were co-cultured with
5T33 tumor cells for 48 hours, supernatants were collected,
Figure 2 Expression of immune checkpoint proteins are increased on T cells in mice treated with sublethal whole body irradiation and
anti-PD-L1. Myeloma bearing KaLwRij mice were treated with 500 cGy whole body irradiation 7 days after tumor cell injection. Treatment with
anti-PD-L1 or control IgG (200 μg ip) was initiated 5 days later and specifically given 12, 14, and 19 days after tumor injection. Mice were euthanized
at day 21, splenocytes were harvested, and the CD8 T cells were analyzed by flow cytometry for immune checkpoint protein expression. (A) Frequency
of CD8+TIM-3+, CD8+LAG-3+ and CD8+2B4+ cells in spleens of anti-PD-L1 treated mice as compared with spleens harvested from control antibody
(IgG1) treated mice. ***p < 0.001. (B) Expression of TIM-3 and PD-1, LAG-3 and PD-1 or 2B4 and PD-1 on gated CD8+ T cells. Data shown are
representative of more than four independent analyses.
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cytokine assay. Similar to results of the IFN-γ ELISPOT as-
says, there was a significant increase in type 1 cytokines
(IL-2, IFN-γ and GM-CSF) produced by CD8 T cells har-
vested from mice that had received anti-PD-L1 in combin-
ation with anti-TIM-3, or anti-LAG-3 or anti-CTLA4 as
compared to anti-PD-L1 alone (Figure 4B). Notably, CD8
T cells from mice treated with anti-PD-L1 in combination
with anti-CTLA4 produced at least 2-fold higher concen-
trations of cytokines as compared to mice treated with
anti-PD-L1 in combination with anti-TIM-3 or anti-LAG-3.
Combined checkpoint blockade results in increased
expression of PD-1 on T cells, and ongoing PD-L1 blockade
in vitro results in elevated numbers of IFN-γ producing cells
There is data suggesting that expression of inhibitory re-
ceptors, including PD-1, correlates with T cell activation
and/or differentiation rather than exhaustion [40]. Other
investigators have also shown that the majority of vaccine-induced CD8+ T cells upregulate PD-1 [41], and PD-1 has
been found on clonally expanded tumor-reactive CD8+ T
cells isolated from tumors [42]. Similarly, we showed that
in mice with 5T33 myeloma, PD-1 expression was upreg-
ulated only on host T cells capable of recognizing tumor
antigens, and not on non-tumor-specific ovalbumin-
reactive OT-1 T cells [39]. In sum, these data indicate
that PD-1 is a marker of activated tumor-specific T cells in
the cancer setting. Based on these observations, we hy-
pothesized that combined immune checkpoint blockade
after lymphodepleting WBI would result in increased per-
centages of T cells that express PD-1, representing in-
creased numbers of myeloma-reactive T cells. Mice were
treated as shown in Figure 3A, except they received only
the first 3 doses of antibody. CD8 T cells were harvested
from the spleen and bone marrow 21 days after tumor in-
jection and were analyzed for PD-1 expression. In support
of our hypothesis, we observed significant increases in
percentages of PD-1+ CD8 T cells in the spleens and bone
Figure 3 Blocking of PD-L1 in combination with TIM-3, LAG-3 or CTLA4 after lymphodepleting whole body irradiation synergistically
improved survival. (A) Experimental design: KaLwRij mice received 500 cGy irradiation 7 days after tumor cell injection. Treatment with blocking
antibody or control IgG (200 μg ip) was initiated 5 days later and specifically given 12, 14, 19, 21, 26, and 28 days after tumor injection. Survival
curves of mice treated with (B) anti-TIM-3 only, or in combination with anti-PD-L1, (C) anti-LAG-3 only, or in combination with anti-PD-L1, (D) anti-CTLA4
only, or in combination with anti-PD-L1, (E) anti-CD48 only, or in combination with anti-PD-L1. Survival was compared with control antibody treated mice
or mice treated with anti-PD-L1 only. Survival curves represent combined data from three (B, C, D) or two (E) independent experiments; n = 10-15 mice
per experimental group. (F) Some of the survivors from panels B, C and D were re-challenged with 1×106 5T33 myeloma cells on day 110. P values were
determined by the log-rank test.
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with anti-TIM-3, anti-LAG-3 or anti-CTLA4 as compared
to anti-PD-L1 alone (Figure 5A).
To explain the increased anti-myeloma immunity after
WBI and checkpoint blockade, we have proposed the
following model: (a) PD-1+ tumor-reactive CD8 T cells
are rendered dysfunctional upon encounter with PD-L1and other checkpoint ligands on the myeloma cells
(5T33 expresses high levels of PD-L1) [39] or other cells
in the microenvironment, (b) that the PD-1+ cells are
able to recover function after WBI due to the transient
lymphopenic state through mechanisms yet to be identi-
fied, and (c) ongoing checkpoint blockade is required to
maintain function of the re-activated T cells. To address
Figure 4 The frequencies of tumor-reactive spleen and bone marrow-derived CD8 and CD4 T cells were increased in mice treated with
a combination of checkpoint blockade. The experimental design shown in Figure 3 was used. Myeloma bearing mice were treated with 3
doses of control IgG, anti-PD-L1 only, or the combination of anti-PD-L1 with anti-TIM-3, or anti-LAG-3 or anti-CTLA4. (A) T cells were isolated from
spleens (top row) and bone marrow (bottom row) 21 days after tumor cell injection (i.e., 14 days after irradiation). CD4+ and CD8+ T cells were
purified by immunomagnetic cell sorting and were tested for IFN-γ production in ELISPOT assays using 5T33-CIITA MHC class II+ or MHC class II−
5T33 wild-type cells as stimulators, respectively. Purified CD8+ or CD4+ T cells for each group were pooled from 5-7 individual mice. The graphs
are representative of three independent experiments. (B) Purified splenic CD8 T cells were stimulated with 5T33 tumor cells for 48 hours.
Supernatants were collected and cytokine levels were determined using a multiplex cytokine assay. The graphs are representative of two
independent experiments in which the CD8+ T cells for each group were pooled from 5 individual mice. For A and B: *p < 0.05, **p < 0.01 as
compared with T cells from mice treated with anti-PD-L1 alone.
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ELISPOT assays on CD8 T cells isolated from mice
treated with 500 cGy WBI and combined checkpoint
blockade, but anti–PD-L1 or control IgG1 antibody was
also added in vitro to the 48-hour CD8 T cell/tumor cell
co-cultures. PD-L1 blockade in vitro significantly in-
creased the frequencies of IFN-γ-producing CD8 T cells
from mice treated with anti-PD-L1 only or combinations
of anti-PD-L1 and other checkpoint blocking antibodies
(Figure 5B). These results highlight the importance of
the PD-1/PD-L1 pathway in suppressing immunity tothe 5T33 myeloma, and they support our model that
ongoing checkpoint blockade is needed to maintain
the function of activated tumor-specific CD8 cells long
enough for them to eliminate the myeloma cells and
generate memory.
Spontaneous and tumor-specific production of Th1 and
Th2 cytokines is elevated from CD4 T cells of mice treated
with anti-PD-L1 plus anti-CTLA4
CD4 T cells from mice treated with WBI and immune
checkpoint blockade were also analyzed for cytokine
Figure 5 Combined blockade of immune checkpoint proteins increased PD-1 expression on CD8 T cells and increased frequency of
tumor specific CTL. The experimental design in Figure 3 was used. Mice were treated with 3 doses of control IgG, anti-PD-L1 only or the combination
of anti-PD-L1 with anti-TIM-3, or anti-LAG-3 or anti-CTLA4. (A) CD8+ T cells were isolated from spleens and bone marrow 21 days after tumor cell injection
and analyzed for PD-1 expression by flow cytometry. (B) IFN-γ produced by CD8 T cells was determined by IFN-γ ELISPOT assays. T cells were incubated
with tumor cells and 10 μg/ml IgG1 or tumor cells and 10 μg/ml anti-PD-L1. The graphs represent 2 independent experiments in which the CD8 T cells
for each group were pooled from 5 to 7 individual mice. P values were determined by the Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.
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were once again treated according to the schedule in
Figure 3A, except they received three antibody doses in-
stead of six. On day 21 after myeloma inoculation, CD4
T cells were harvested from the spleen and purified by
immunomagnetic cell sorting. Cells were incubated with
5T33-CIITA tumor cells expressing MHC class II mole-
cules for 48 hours followed by cytokine analysis in
multiplex cytokine assays. Spontaneous cytokine release
was analyzed by incubating CD4 T cells alone or with
wild-type 5T33 cells. CD4 T cells harvested from mice
treated with anti-PD-L1 plus anti-CTLA4 spontaneously
released IFN-γ, as well as the Th2 cytokines IL-4 and
IL-5 (Figure 6). Cytokine release was significantly in-
creased when the T cells were incubated with 5T33-
CIITA MHC class II+ tumor. CD4 T cells harvested
from mice treated with anti-PD-L1 plus anti-LAG-3 or
anti-TIM-3 also released IFN-γ when stimulated with5T33-CIITA cells, but there was no spontaneous or
tumor-induced release of IFN-γ, IL-4 and IL-5.
Discussion
From our results to date, we propose a working model
whereby low dose WBI generates a transient state of lym-
phopenia, which allows for the reactivation of myeloma-
reactive T cells that have been rendered dysfunctional by
checkpoint proteins. Checkpoint blockade then allows the
re-activated T cells to remain functional and eliminate the
myeloma. Lymphodepleting WBI and PD-L1 blockade
failed in two solid tumors, but provided anti-tumor effi-
cacy in other murine hematologic malignancy models,
suggesting that hematologic malignancies may be more
amenable to this treatment strategy [39]. The current
study furthers the earlier work by demonstrating that
myeloma experienced T cells upregulate expression of
multiple checkpoint receptors including PD-1, LAG-3,
Figure 6 There is spontaneous release of Th1 and Th2 cytokines from splenic CD4 T cells harvested from mice treated with anti-PD-L1
and anti-CTLA4. The experimental design shown in Figure 3 was used. Mice were treated with anti-PD-L1, or the combination of anti-PD-L1 with
anti-TIM-3, or anti-LAG-3 or anti-CTLA4. T cells were isolated from spleens 21 days after tumor cell injection (14 days after irradiation). CD4 T cells
were purified by immunomagnetic cell sorting, then stimulated with MHC class II− 5T33 wild-type cells, 5T33-CIITA MHC class II+ cells or T cells
only for 48 hours. Supernatants were collected and cytokine levels from were determined using a multiplex cytokine assay. The graphs are representative
of two independent experiments in which the CD4+ T cells for each group were pooled from 5 individual mice. p < 0.05, **p < 0.01.
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bearing mice with lymphodepletive WBI and dual check-
point blockade induced a synergistic anti-myeloma effect,
and this enhanced elimination of myeloma was associated
with increased numbers of IFN-γ-producing tumor-
reactive T cells and elevated cytokine production by T cells
in response to tumor antigens.
Multiple immune checkpoints have been previously
shown to be upregulated on T cells in several murine solid
tumor models, and targeting more than one pathway has
demonstrated increased anti-tumor efficacy [19,21,22,43-52].
However, there is a paucity of literature regarding expression
of immune checkpoints on T cells in hematologic malignan-
cies or the effect of targeting more than one checkpoint as
therapy for these cancers [22]. Clinically, PD-1 and CTLA4
have been simultaneously targeted for the treatment of mel-
anoma, and anti-tumor activity appears to be more robust
than targeting each pathway alone [15]. Notably, auto-
immune manifestations with this combination did not ap-
pear to be significantly worsened. In our studies, blockade of
the PD-1/PD-L1 pathway appears to provide an activation
threshold for myeloma-reactive T cells that allows blockade
of other checkpoints to provide synergistic anti-myeloma re-
sponses. Interestingly, blockade of LAG-3, TIM-3 or CTLA4
alone had only modest or no effect on elimination of mye-
loma after WBI. How inhibitory signals transmitted through
TIM-3 and LAG-3 synergize with those transmitted through
PD-1 is unknown. It could be that there is constitutive in-
hibitory signaling through TIM-3 and LAG-3 by the pres-
ence of pleotropic ligands (Additional file 2: Figure S2). The
blocking of these constitutive inhibitory signals may have an
observable anti-tumor effect only when dominant inhibitory
signaling through PD-1 is blocked. In contrast, when com-
bined with PD-L1 blockade, potent anti-myeloma effects
were observed when each of these pathways was targeted
(Figure 3).Treatment with WBI and anti-PD-L1 resulted in in-
creased expression of PD-1 as well as LAG-3, TIM-3
and 2B4 (Figure 2). Furthermore, blockade of PD-L1
with other immune checkpoints (TIM-3, LAG-3 and
CTLA4) drove up PD-1 expression on T cells even fur-
ther (Figure 5A). This result is surprising, as the expres-
sion of checkpoint receptors on T cells have been
regarded as markers of dysfunction. In settings of chronic
antigen exposure, such as cancer, expression of checkpoint
receptors such as PD-1, CTLA4, TIM-3, LAG-3, and 2B4
have been associated with dysfunctional T cells, often
termed exhausted or tolerized [53-57]. However, there are
recent reports that PD-1+ T cells may not be functionally
impaired, but instead represent T cells that have been acti-
vated. In healthy adults, PD-1+ peripheral CD8 T cells
were shown to be effector memory cells and not exhausted
T cells [58]. In support of this data, Baitsch et al. found
that the majority of human effector memory T cells
co-expressed PD-1, CTLA4, KLRG-1, 2B4, LAG-3 or
CD160 [59]. Also, in human CD8 T cells, an increase
in co-expression of inhibitory receptors such as PD-1,
TIM-3, 2B4, CD160 and KLRG1 correlated with T cell
differentiation or activation status [40]. In support of
these findings we found that sorted PD-1+ tumor-
experienced CD8 T cells secrete IFN-γ when in vitro
incubated with myeloma cells and anti-PD-L1 blocking
antibody (unpublished data). The mechanism(s) by
which checkpoint receptors are regulated by blocking
antibodies and how this induces T cell activation is cur-
rently unknown. In order to dissect the mechanism(s) in-
volved, further investigation of the myeloma-reactive T
cells is required. Since the tumor antigens in the 5T33
tumor model are unknown, we have genetically modi-
fied 5T33 cells to express a model antigen, SIINFEKL
ovalbumin peptide, so that we can detect and isolate
‘tumor-specific’ cells using a MHC/SIINFEKL pentamer
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and isolated, the mechanism of how checkpoint blockade
regulates checkpoint expression can be interrogated.
Currently, there is no reliable way to predict which pa-
tients are going to benefit from checkpoint blockade.
However, our data may provide clues as to which com-
bination of checkpoint molecules to block based on the
expression pattern of checkpoint receptors on T cells.
We observed increased expression of TIM-3, LAG-3,
CTLA4, and 2B4 on both CD8 and CD4 T cells in
myeloma-bearing mice, and anti-myeloma synergy occurred
when the PD-1/PD-L1 axis was blocked in combination
with blocking TIM-3, LAG-3, or CTLA4. Despite upregula-
tion of 2B4 on T cells with increasing myeloma burden,
which has also been observed on CD8 and CD4 T cells in a
mouse pancreatic cancer model [60], blockade of PD-L1
plus the ligand for 2B4, CD48, did not provide any add-
itional benefits over PD-L1 blockade alone. It is possible that
the CD48-specific antibody used in this study did not block
the 2B4/CD48 receptor axis, although the antibody clone
used has been reported to block the pathway [61]. Another
possible reason for the lack of synergy stems from a report
that 2B4 has both T cell proliferative and inhibitory effects
[32]. Recently, CD48 was found to be expressed on more
than 90% of plasma cells from myeloma patients at higher
levels than those observed on normal lymphocytes [62], al-
though it is unknown whether this elevated expression
could have a negative impact on T cell reactivity. This will
need to be examined more closely in future studies.
As noted earlier, we observed anti-myeloma synergy
when mice were treated with anti-PD-L1 and anti-CTLA4
blocking antibodies. In clinical trials, treatment with anti-
CTLA4 has been associated with multiple immune-
related adverse events including colitis, hepatitis, and
thyroiditis [63]. Treatment of patients with antibodies
targeting the PD-1/PD-L1 pathway has also resulted in
some toxicities, although they have typically been less
severe than those observed with CTLA4 antibodies
[64]. We did not observe weight loss or any gross toxic-
ities in mice treated with anti-PD-L1 and anti-CTLA4,
despite the fact that this checkpoint blockade combination
produced significantly more Th1 and Th2 cytokines than
anti-PD-L1 in combination with anti-TIM-3 or anti-LAG-
3 (Figures 4B and 6). Notably, the frequencies of IFN-γ-
producing tumor-reactive CD8 T cells from anti-PD-L1/
CTLA4 treated mice were similar to those treated with
the anti-PD-L1/LAG-3 and anti-PD-L1/TIM-3 combina-
tions (Figures 4A and 5B). However, since the bulk pro-
duction of IFN-γ was increased (Figure 4B), it appears
that tumor-reactive CD8 T cells in anti-PD-L1/CTLA4
treated mice produce more cytokines on a per cell basis.
Similar to this observation, combined immunotherapy
using OX40 stimulation with CTLA4 inhibition enhanced
Th1 and Th2 cytokine production by effector T cells [65].T regulatory function was not inhibited by this ap-
proach. In our study, there were no differences in the
percentages of Gr-1+CD11b+ myeloid cells or regula-
tory T cells in the spleens of myeloma-bearing mice
treated with anti-PD-L1 plus anti-CTLA4 as compared
to anti-PD-L1 plus other checkpoint antibodies (Additional
file 3: Figure S3). These data suggest that these cells may
not be involved with regulating T cell cytokine production.
However, confirmatory functional studies remain to be
done. It is possible that anti-tumor synergy produced by
anti-PD-L1 in combination with anti-LAG-3 or anti-TIM-
3 antibodies may be a less toxic alternative to anti-PD-L1
in combination with anti-CTLA4 antibodies.
Finally, it is important to note that we previously re-
ported treatment with a lymphodepleting dose of 500 cGy
WBI prior to treatment with anti-PD-L1 was a prerequisite
for generating effective anti-myeloma immunity [39].
Therefore, in the current study we also treated mice with
500 cGy WBI prior to administering checkpoint-blocking
antibodies. The mechanisms of how WBI sensitizes the im-
mune system to produce effective checkpoint blockade has
yet to be determined. Multiple immune factors may be im-
portant such as providing a lymphopenic environment to
induce homeostatic expansion of tumor-reactive T cells.Conclusions
In summary, we show that combined immune check-
point blockade provides a synergistic anti-myeloma ef-
fect in mice treated with low dose, lymphodepleting
WBI. The anti-myeloma effect correlates with activation
of T cells, which appears to be maintained by checkpoint
blockade. The importance of sustaining immune checkpoint
blockade until tumor cells are eliminated is highlighted by
the positive impact addition of anti-PD-L1 had on IFN-γ-
producing T cells when added to T cell/myeloma cell
co-cultures in ELISPOT assays (Figure 5B). Increased
T cell expression of checkpoint molecules following
checkpoint blockade suggests that expression of these
molecules is an indicator of T cell activation, rather
than a state of irreversible exhaustion. Given our anti-
myeloma results using checkpoint blockade, continued
study of checkpoint blockade in other hematologic malig-
nancies is warranted. In future studies, it will be interest-
ing to see if targeting more than two checkpoint pathways
simultaneously in myeloma and other hematologic malig-
nancies can further improve anti-tumor immunity without
generating unacceptable autoimmunity. Understanding
the mechanisms of tumor cell elimination induced by
combined checkpoint blockade and low dose WBI, and
determining if other lymphodepleting strategies can be
used, such as lymphodepleting drugs or low doses of T cell
depleting antibodies, will help to expand the translational
applications of this approach. Finally, this therapeutic
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therapies, including T cell adoptive transfer.
Methods
Mice
C57BL/KaLwRij (KaLwRij) and (KaLwRij × C57BL/
6.SJL)F1 mice were bred and housed in the Medical College
of Wisconsin Biomedical Resource Center, which is an
American Association for the Accreditation of Laboratory
Animal Care (AAALAC)–accredited facility. All animal
work was reviewed and approved by the Medical College of
Wisconsin Institutional Animal Care and Use Committee.
Tumor cells
The 5T33 murine myeloma cell line was derived from a
myeloma that spontaneously arose in a C57BL/KaLwRij
mouse [40]. 5T33 cells were transduced to express emer-
ald green fluorescent protein (5T33-GFP), as previously
described [39]. MHC class II+ 5T33 cells (designated
5T33-CIITA) were derived by transducing 5T33 cells
with a lentiviral expression vector (PLVX-N1; ClonTech,
Mountain View, CA) encoding the MHC class II trans-
activator (CIITA) gene. Mice were inoculated with 2×106
5T33 or 5T33-GFP cells intravenously (iv). Myeloma-
bearing mice were considered as moribund and eutha-
nized when they developed paraparesis or paraplegia.
Occasionally, 5T33-injected mice developed tumor masses
or other related lesions and were euthanized when the size
of the mass or lesion exceeded 250 mm2. Other symptoms
of advanced tumor burden included splenomegaly, hep-
atomegaly, or neurologic impairment.
Antibodies and flow cytometry
The following monoclonal anti-mouse antibodies and
flow cytometry reagents were obtained from eBioscience
(San Diego, CA): anti-CD4 (GK1.5), anti-CD8 (53-6.7),
anti-PD-1 (J43), anti-TIM-1 (RMT1-4), anti-TIM-3 (RMT3-
23), anti-LAG-3 (C987W), anti-2B4 (244F4), anti-CTLA4
(UC10-4F10-11), anti-BTLA (8F4), anti-PD-L1 (MIH5),
anti-galectin-9 (108A2), anti-I-Ab (AF6-120.1), anti-CD80
(16-10A1), anti-H2Kb (AF6-88.5.5.3), anti-CD11b (M170),
anti-CD11c (N418), anti-F4/80 (BM8), anti-Gr-1 (RB6-
8C5), anti-Foxp3 (FJK-16 s) and propidium iodide staining
solution. The following antibodies and reagents were
obtained from Biolegend (San Diego, CA): anti-CD8
(53-6.7), anti-PD-1 (J43), and anti-TIM-3 (B8.2C12),
anti-CD19(GD5). Flow cytometry was done on a BD
Biosciences (Franklin Lakes, NJ) LSRII flow cytometer,
and resulting data analyzed using FlowJo software
(Tree Star, Inc.).
Antibody treatment of myeloma-bearing mice
C57BL/KaLwRij or (KaLwRij × C57BL/6.SJL)F1 mice were
injected with 2×106 5T33 cells iv. The myeloma bearingmice were irradiated with 500 cGy whole body irradiation
(WBI) using a cesium irradiator 7 days after myeloma in-
oculation. Antibody treatment was initiated 5 days after
WBI and administered on days 12, 14, 19, 21, 26, and 28
after myeloma inoculation. 5T33 tumor-bearing mice
were treated with anti-PD-L1 (clone 10F.9G2; BioXCell),
anti-LAG-3 (clone C9B7W), anti-TIM-3 (clone 5D12;
CoStim/Novartis), anti-CTLA4 (clone 9H10; BioXCell), or
anti-CD48 (clone HM48-1; BioXCell) monoclonal anti-
bodies at the indicated time points. Some mice received a
combination of anti-PD-L1 plus anti-LAG-3, anti-TIM-3
or anti-CTLA4. Rat immunoglobulin G (IgG) was admin-
istered as control antibody. All antibodies were given at a
dose of 200 μg by intraperitoneal (ip) injection. Myeloma-
bearing mice were considered as moribund and eutha-
nized when they developed hind-leg paralysis or other
defined endpoints. Mice that survived the initial treat-
ment were re-challenged with 1×106 5T33 tumor cells
100-110 days after the first inoculation.
Interferon-gamma (IFN-γ) ELISPOT assays
To assess for presence of tumor-reactive, interferon-
gamma (IFN-γ)-secreting CD8 or CD4 T cells, T cells
were harvested from the spleen and bone marrow, and
isolated by immunomagnetic cell sorting as previously
described [35]. IFN-gamma enzyme-linked immunosorb-
ent spot (ELISPOT) assays were done using mouse IFN-γ
ELISPOT kits from BD Biosciences, as described pre-
viously [39]. The ELISPOT data was quantified using a
Cellular Technology Limited (CTL) ImmunoSpot Analyzer
(CTL Analyzers, Cleveland, OH).
Bio-plex cytokine assays
CD4 and CD8 T cells from antibody treated myeloma-
bearing mice were cultured in media alone or in the
presence of 5T33 wild type or 5T33-CIITA tumor cells.
Culture supernatants were harvested after 48 hours and
stored at −80°C. Thawed supernatants were then ana-
lyzed using a murine multiplex cytokine kit (Bio-Rad,
Hercules, CA) to detect IL-2, IL-4, IL-5, IL-10, IL-12p70,
granulocyte-macrophage colony stimulating factor (GM-
CSF), tumor necrosis factor-alpha (TNF-α), and IFN-γ.
Cytokines were quantified using a Bio-Plex protein 200
array reader, and data was automatically processed and
analyzed by the Bio-Plex Manager Software 4.1 using
standard curves generated from recombinant cytokine
standards. All samples were assayed in duplicate.
Statistics
Survival curves were compared using the log-rank (Mantel
Cox) test. Other experiments were compared using the
Student’s t test. P values <0.05 were considered as signifi-
cant. Statistical analysis was done using Prism version 5.0a
software (GraphPad Software, La Jolla, CA).
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Additional file 1: Figure S1. Expression of immune checkpoint
proteins on T cells in spleens of myeloma bearing mice over time.
KaLwRij mice were inoculated with 2×106 5T33-GFP cells iv. Myeloma
bearing mice were euthanized between days 7 and 28 and when moribund
at days 29-40 after myeloma injection. Spleens were harvested and CD4+ and
CD8+ T cells were analyzed for immune checkpoint protein expression over
time by flow cytometry. T cells harvested from naïve nonmyeloma bearing
mice were analyzed as controls. Immune checkpoint protein percentages
were calculated based on isotype controls. *p < 0.05, **p < 0.01, ***p < 0.001
as compared to T cells from naïve non-myeloma bearing mice.
Additional file 2: Figure S2. Membrane expression of immune
checkpoint protein ligands on myeloma and splenocytes. (A) PD-L1,
galectin-9, MHC class II (I-Ab) and CD80 expression on 5T33 tumor cells
(solid line), and on 5T33 tumor cells irradiated in vitro with 500 cGy
(dashed line). Isotype controls are shaded in gray. (B) Expression of PD-L1,
galectin-9, MHC class II (I-Ab) and CD80 on B cells, macrophages, dendritic
cells (DC) and monocytes in the spleens of moribund myeloma-bearing
mice. Fluorescence minus one (FMO) controls are shaded in gray.
Additional file 3: Figure S3. Percentages of myeloid and regulatory T cells
in the spleens of mice treated with combinations of blocking antibodies to
immune checkpoint proteins. Mice were treated as shown in Figure 3A.
Myeloma bearing mice were treated with three doses of control IgG, anti-PD-L1
only, or a combination of anti-PD-L1 with anti-TIM-3, anti-LAG-3 or anti-CTLA4.
At day 21 after myeloma inoculation, spleens were harvested and the
percentages of Foxp3+CD4+ regulatory T cells and Gr-1+CD11b+ myeloid
cells were analyzed by flow cytometry.
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